Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Green

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
BMC Cancer|December 22, 2007
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancerMatthew A Beldner, Carol A Sherman, Mark R Green, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 1, 2012
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206Michael J Kelley, Jeffrey A Bogart, Lydia D Hodgson, et al.
Journal of Surgical Oncology|October 14, 2006
Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935Michael T Jaklitsch, James E Herndon, Malcolm M DeCamp, et al.
Clinical Lung Cancer|August 16, 2005
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534Wallace Akerley, James E Herndon, Alan P Lyss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)Antonius A Miller, Xiaofei F Wang, Lin Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904Robert A Kratzke, Xiaofei Wang, Long Wong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 28, 2008
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235Jeffrey A Bogart, Dorothy Watson, Edward F McClay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2007
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002Antonius A Miller, Xiaofei F Wang, Jeffrey A Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2005
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group BA William Blackstock, James E Herndon, Electra D Paskett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateCaio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
BMC Cancer|December 22, 2007
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancerMatthew A Beldner, Carol A Sherman, Mark R Green, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 1, 2012
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206Michael J Kelley, Jeffrey A Bogart, Lydia D Hodgson, et al.
Journal of Surgical Oncology|October 14, 2006
Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935Michael T Jaklitsch, James E Herndon, Malcolm M DeCamp, et al.
Clinical Lung Cancer|August 16, 2005
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534Wallace Akerley, James E Herndon, Alan P Lyss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)Antonius A Miller, Xiaofei F Wang, Lin Gu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904Robert A Kratzke, Xiaofei Wang, Long Wong, et al.
Lung Cancer (Amsterdam, Netherlands)|March 28, 2008
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235Jeffrey A Bogart, Dorothy Watson, Edward F McClay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2007
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002Antonius A Miller, Xiaofei F Wang, Jeffrey A Bogart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2005
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group BA William Blackstock, James E Herndon, Electra D Paskett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateCaio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Pageof 7